Skip to content

Research on Ringworm in Unani Medicine

A Comparative Study on the Efficacies of Joshanda Haleela Siyah with topical zimads in Qooba (Tinea Corporis )-A Randomized Single Blind Controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053844
Enrollment
40
Registered
2023-06-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Oral :Joshanda Haleela Siyah Topical : Zimad of Tukhm e Panwad , Kunjad Siyah , Sarshaf: In the patients of group A, Joshanda Haleela Siyah is administered orally empty stomach in the m

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed cases of Tinea Corporis with less than or equal to 3% body surface area (calculated by the palm rule)Patients whose KOH is positive. 2. Patient of either gender. 3. Age group 18-60 years. 4).Patient with controlled diabetes

Exclusion criteria

Exclusion criteria: 1.Known cases of tinea corporis on medication one month prior 2. Patients of T. Corporis with more than 3% body surface area. 3. Patients whose KOH is negative. 4. Patients below and above the age of 18 and 60 years respectively. 5. Patients suffering from concomitant skin diseases like psoriasis & Eczema and other types of tinea like T. Cruris, T. Facei, T.Capitis, T.Unguum, T.Manuum. 6. Pregnant & Lactating Women. 7. Known history of impaired hepatic, renal or cardiovascular functions in patients. 8. Uncontrolled cases of Diabetes and other immunocompromised patients

Design outcomes

Primary

MeasureTime frame
Primary End Points: complete clearance among groups at the end of the intervention Secondary End Points: a) Comparison of achieved clinical cure among groups at the end of the intervention Timepoint: 3 Weeks

Secondary

MeasureTime frame
Secondary End Points: a) Comparison of achieved clinical cure among groups at the end of the intervention b) Comparison of achieved Mycological cure among groups at the end of the interventionTimepoint: 3 Weeks

Countries

India

Contacts

Public ContactProf Mohd Aleemuddin Quamri

National Institute Of Unani Medicine

iramnaaz144@gmail.com9916233452

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026